U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07165132) titled 'Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.' on Aug. 20.
Brief Summary: The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Study Start Date: Oct., 2025
Study Type: INTERVENTIONAL
Condition:
GEP-NET
Gastroenteropancreatic Neuroendocrine Tumor
Gastroenteropancreatic Neuroendocrine Tumor Disease
Neuroendocrine Tumors
Carcinoid
Carcinoid Tumor
Pancreatic NET
Solid Tumor
Somatostatin Receptor
Intervention:...